Keywords: Avastin, Roche, Genentech, Breast cancer, USA, FDA hearing
US FDA allows Genentech/Roche to present case for Avastin in metastatic breast cancer
Article | 25 February 2011
In what is seen as a first-of-a-kind decision, the US Food and Drug Administration has granted a hearing to allow ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
